Particularly, loss of TP53 and RB1, mutations in SOX family genes, activation of the PI3K/AKT pathway and amplification of MYC and AURKA collectively drive SCLC features77, 124 (Figure 2E). This evidence concerns the gene TP53 and small cell lung carcinoma.